+

US20130327676A1 - Packaging of Solid Pharmaceutical Preparations Containing the Active Substance Glyceryl Trinitrate - Google Patents

Packaging of Solid Pharmaceutical Preparations Containing the Active Substance Glyceryl Trinitrate Download PDF

Info

Publication number
US20130327676A1
US20130327676A1 US14/001,032 US201214001032A US2013327676A1 US 20130327676 A1 US20130327676 A1 US 20130327676A1 US 201214001032 A US201214001032 A US 201214001032A US 2013327676 A1 US2013327676 A1 US 2013327676A1
Authority
US
United States
Prior art keywords
pharmaceutical preparation
gtn
composite film
active substance
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/001,032
Inventor
Thomas Zimmeck
Henning Ueck
Julia Zscherpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G Pohl Boskamp GmbH and Co KG
Original Assignee
G Pohl Boskamp GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Pohl Boskamp GmbH and Co KG filed Critical G Pohl Boskamp GmbH and Co KG
Assigned to G. POHL-BOSKAMP GMBH & CO. KG reassignment G. POHL-BOSKAMP GMBH & CO. KG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GEHRICKE (NEE ZSCHERPE), JULIA, UECK, HENNING, ZIMMECK, THOMAS
Publication of US20130327676A1 publication Critical patent/US20130327676A1/en
Assigned to G. POHL-BOSKAMP GMBH & CO. KG reassignment G. POHL-BOSKAMP GMBH & CO. KG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GEHRICKE (NÉE ZSCHERPE), JULIA, UECK, HENNING, ZIMMECK, THOMAS
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Definitions

  • the present invention relates to solid pharmaceutical preparations containing volatile active substances in the form of one or more individual doses packaged in specific composite films or blister foils with improved storage stability.
  • the present invention relates to solid pharmaceutical preparations for oral or oromucosal administration containing the active substance glyceryl trinitrate (nitroglycerin, referred to below in abbreviated form as GTN) in the form of pre-dosed granules or in the form of tablets, which are packaged individually in a stick pack, a four-sided sealed pouch or a blister, respectively.
  • GTN active substance that is packaged individually in a stick pack, a four-sided sealed pouch or a blister, respectively.
  • GTN is an active substance which is used in the treatment of attacks of angina pectoris, among other uses, whereby it is especially used in emergency situations, in which the pharmaceutical form must enable a rapid onset of action.
  • sublingual administration has proven very effective with rapid uptake of the active substance and quick relief of symptoms.
  • tablets for oromucosal, i.e. sublingual or buccal administration with rapid onset of action have proven to be especially effective pharmaceutical forms for the outpatient sector.
  • Sprays for sublingual administration which are used to spray the active substance-containing dose underneath the tongue, provide for a direct and rapid application of the dissolved active substance over a large area of the highly resorbent oral mucosa.
  • affected patients are required to carry a relatively voluminous spray bottle around with them at all times in order to ensure immediate access to the medicinal product in emergencies and enable a rapid administration of the GTN.
  • chewable capsules containing the active substance as an oily solution can be carried around as individual doses in blisters.
  • a portion of the active ingredient which is released by tearing open the capsules with the teeth, never reaches the sublingual area, its absorption is delayed or it is lost through swallowing.
  • Sublingual tablets and oral fast dissolving films represent a further alternative to spray solutions and chewable capsules because they can be placed directly under the tongue to rapidly release the active substance.
  • GTN tablets Up to now commercially available GTN tablets have been filled into glass bottles, which are relatively inert against interactions with the filled product. In addition, they are transparent and protect the contents from external influences. However, due to their low shatter resistence glass containers must be handled with a certain level of caution when carried around by patients. In addition, due to the small size of the tablets the removal of a single tablet can be difficult in an emergency situation, when patients can easily drop the container. Moreover, it is not practical to package individual doses in glass containers and the patients are required to carry around the entire original packaging. For this reason, there is the long felt unmet need for solid and stable pharmaceutical forms for GTN, which are easy for patients to carry around in single-dose form, e.g. in a wallet or jacket pocket, and which simultaneously ensure sufficient stability, simple administration, and rapid onset of action.
  • So-called stick packs or sachets represent an alternative configuration for individual doses, which are becoming increasingly common in the pharmaceutical industry.
  • Stick packs are typically manufactured using composite films consisting of several layers, whereby each individual layer of film performs a specific task (barrier, stiffness, impact resistance, sealing properties, etc.).
  • the barrier layer performs the task of protecting the package contents against substance loss and external contamination.
  • a support layer stabilizes the packaging, enabling it to withstand mechanical stresses, while the sealing layer serves mainly to seal the film package. It is usually made of a thermoplastic polymer and is located on the side of the composite film facing the filling material.
  • Stick packs can be manufactured to contain the pharmaceutical preparation as flowable granules or powder and enable both comfortable transport of the medicinal product as well as simple, easy and reproducible dosing, which is especially significant in emergency situations.
  • GTN granules with their substantially larger total surface area as compared to tablets—pose an even greater challenge with respect to the stabilization of the preparation in any type of packaging configuration including stick packs.
  • the highest possible storage stability is especially critical to enable the patient to carry around a single dose such as, but not limited to a stick pack.
  • carrying it around in the breast pocket of a shirt for example, can subject it to significant temperature increases and associated stress conditions, which may violate the recommended storage conditions for GTN preparations.
  • OFDF oral fast dissolving film
  • GTN has a high affinity for organic materials.
  • organic materials such as cork, cotton, paper, and especially rubber and polyethylene to store GTN-containing tablets must be avoided.
  • Banes Journal of Pharmaceutical Sciences, 57, 1968, 893 reported GTN loss in tablets packaged individually in aluminum foil films containing a sealing layer made of polyethylene. Following storage, the tablets were found to have less than 10% of the active substance they originally contained, while the majority of the GTN was found in the sealing layer of the packaging material.
  • a primary packaging material suitable for the production of individual doses e.g. in the form of stick packs, must be flexible and sufficiently stable in order to avoid being destroyed during transport.
  • the packaging material must be inert and impervious to the active substance as well as to impurities, which can reach the preparation from the outside.
  • a series of materials is available in the form of composite films for the production of stick packs, sachets and blisters.
  • aluminum composite films are especially suited for the packaging of pharmaceutical preparations which should be protected from external influences. They exhibit the following layer structure:
  • These films possess suitable mechanical stability and are impervious to both external contaminants as well as to volatile substances contained in the preparation.
  • the paper or PET layer is located on the external surface of the packaging and can be imprinted for their identification.
  • the surface of the aluminum film coming into contact with the filling material is provided with a sealing medium.
  • Sealing materials differ in certain physico-chemical properties, e.g. the softening temperature and a possible interaction with the components of the pharmaceutical preparation. Available materials include composite films with polyethylene (PE), polypropylene (PP), low-density polyethylene (LDPE) or polyacrylonitrile (PAN) as sealing layer.
  • PE polyethylene
  • PP polypropylene
  • LDPE low-density polyethylene
  • PAN polyacrylonitrile
  • PAN comprises polyacrylonitrile as well as copolymers of acrylonitrile units and one or more other monomers (AN-copolymers) such as acrylonitrile-methylacrylate copolymer.
  • blisters consisting of an aluminum push-through foil and a thermoplastic film are also available for packaging tablets.
  • Suitable thermoplastic films include thermoplastic composite films, which typically consist of multiple layers of different plastics, such as PE, PVC, PP, LDPE or PAN.
  • the mentioned packaging materials are also suitable for other kinds of dosage forms available for individual doses such as powders and orally fast dissolving films.
  • the object of the present invention is to provide a solid pharmaceutical preparation containing GTN for oral and oromucosal (such as sublingual or buccal) administration in the form of individually packaged single doses having good storage stability.
  • a stable medicament comprising a solid pharmaceutical preparation containing the active substance GTN for oral or oromucosal administration in the form of one or more individual doses, wherein the one or more individual doses are packaged in aluminium composite films or thermoplastic blister films, which contain a layer comprising PAN on the side facing the preparation.
  • solid GTN-containing preparations remain stable for the required time period if they are packaged in composite films containing a layer comprising PAN on the surface facing the product.
  • Preferred are aluminum composite films containing a sealing layer comprising an acrylonitrile-methylacrylate copolymer, while aluminium composite films containing a sealing layer made of an impact-modified acrylonitrile-methylacrylate copolymer are particularly preferred.
  • barrier plastics are marketed, among others, under the commercial names Barex® 210 or Barex® 218.
  • the preparations according to the invention are packaged as individual doses which remain stable for a storage period of at least 6 months at 40° C. and 75% relative humidity.
  • the preferred pharmaceutical preparation is an oromucosal, solid, GTN-containing preparation, preferably a GTN-containing, flowable powder or flowable granules, respectively, for sublingual administration, which may optionally be pressed into a sublingual tablet.
  • the pharmaceutical preparation contains 0.05 to 2 weight % GTN; GTN concentrations of 0.10, 0.20, 0.25, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 1.0, 1.2, 1.4, 1.6 or 1.8 weight % are especially preferred. Unless otherwise stated, all weight percentages are based on the total weight of the preparation.
  • the pharmaceutical preparation according to the invention may contain one or more other pharmaceutical excipients, which support sublingual release of the active substance and which are selected from water-soluble mono-, di-, and polysaccharides, as well as their alcohols.
  • These excipients are especially selected from fructose, glucose, isomalt, lactose, maltitol, maltose, mannitol, saccharose, sorbitol, trehalose and xylitol, and mixtures thereof.
  • These excipients are preferably present in a total content of 90 to 98 weight %. In the case of mixtures, the concentration of each individual substance is 20 to 70 weight %, whereby the preferred contents include 25, 30, 35, 40, 45, 50, 55, 60 or 65 weight %.
  • the preparation according to the invention may optionally be provided with a coating.
  • the preparation according to the invention may contain other excipients, such as flavoring agents.
  • Flavoring agents are used especially in the case of preparations for oral or sublingual administration in order to increase acceptance among patients. According to the invention, they are preferably used at concentrations of 0.01 to 3.0 weight %, whereby the especially preferred concentrations include 0.5, 1, 1.5, 2 or 2.5 weight %.
  • GTN intended for pharmaceutical purposes is phlegmatized by the manufacturer, i.e. embedded in a matrix, which reduces the risk posed by the hazardous properties.
  • the matrix can be in liquid or in powder form.
  • GTN is available as a 5% solution in medium-chain triglycerides, such as Miglyol® 812 or Miglyol® 840, or propylene glycol, as a 10% lactose triturate or a 2.25% dilution in glucose. If these GTN concentrates are used for producing the pharmaceutical preparation according to the invention, the agent used for phlegmatization of GTN is regularly contained in the finished product. If GTN is phlegmatized in a volatile solvent like ethanol, the solvent can be lost during the production process.
  • GTN was used as a 5% concentrate in Miglyol® 812. Unless otherwise stated, the optionally pre-granulated excipients were processed into a homogenous mixture with the GTN concentrate.
  • Example 1 The granules according to Example 1 were packaged in the packaging materials referred to in Examples 2 through 5 and stored for 12 weeks at 25° C. and 60% relative humidity and at 40° C. and 75% relative humidity. As a reference, granules were stored in open dishes and in glass containers.
  • PET aluminum—75 ⁇ m LDPE (low-density polyethylene)
  • PET aluminum—50 ⁇ m PP (polypropylene)
  • PET aluminum—50 ⁇ m PAN (Barex® 210)
  • the preparation according to the present invention can be supplied as individual dose, e.g. within a stick pack or sachet, wherein the aluminum composite film contains a layer comprising PAN on the side facing the preparation.
  • Single doses of GTN in form of tablets, pellets or capsules can likewise be filled in stick packs and sachets or packaged in blisters, whose thermoplastic film surface contains a layer comprising PAN on the side facing the preparation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Solid pharmaceutical preparation containing the active substance glyceryl trinitrate in the form of a single dose for sublingual or oral administration, which is packaged in a composite film, wherein the composite film contains a layer comprising polyacrylonitrile (PAN) on the side facing the preparation.

Description

  • The present invention relates to solid pharmaceutical preparations containing volatile active substances in the form of one or more individual doses packaged in specific composite films or blister foils with improved storage stability. In particular, the present invention relates to solid pharmaceutical preparations for oral or oromucosal administration containing the active substance glyceryl trinitrate (nitroglycerin, referred to below in abbreviated form as GTN) in the form of pre-dosed granules or in the form of tablets, which are packaged individually in a stick pack, a four-sided sealed pouch or a blister, respectively.
  • GTN is an active substance which is used in the treatment of attacks of angina pectoris, among other uses, whereby it is especially used in emergency situations, in which the pharmaceutical form must enable a rapid onset of action. Within this framework sublingual administration has proven very effective with rapid uptake of the active substance and quick relief of symptoms. In addition to sublingual sprays and chewable capsules, tablets for oromucosal, i.e. sublingual or buccal administration with rapid onset of action have proven to be especially effective pharmaceutical forms for the outpatient sector.
  • Sprays for sublingual administration, which are used to spray the active substance-containing dose underneath the tongue, provide for a direct and rapid application of the dissolved active substance over a large area of the highly resorbent oral mucosa. However, affected patients are required to carry a relatively voluminous spray bottle around with them at all times in order to ensure immediate access to the medicinal product in emergencies and enable a rapid administration of the GTN. Alternatively, chewable capsules containing the active substance as an oily solution can be carried around as individual doses in blisters. However, a portion of the active ingredient, which is released by tearing open the capsules with the teeth, never reaches the sublingual area, its absorption is delayed or it is lost through swallowing. Sublingual tablets and oral fast dissolving films (also referred to as edible films) represent a further alternative to spray solutions and chewable capsules because they can be placed directly under the tongue to rapidly release the active substance.
  • With a vapor pressure value of 0.25 Pa at 20° C., GTN is volatile in liquid as well as in solid formulation. Thus, it has been observed that tablets lose some of the active substance merely by opening the package to remove some of them, resulting in a limited shelf life.
  • Up to now commercially available GTN tablets have been filled into glass bottles, which are relatively inert against interactions with the filled product. In addition, they are transparent and protect the contents from external influences. However, due to their low shatter resistence glass containers must be handled with a certain level of caution when carried around by patients. In addition, due to the small size of the tablets the removal of a single tablet can be difficult in an emergency situation, when patients can easily drop the container. Moreover, it is not practical to package individual doses in glass containers and the patients are required to carry around the entire original packaging. For this reason, there is the long felt unmet need for solid and stable pharmaceutical forms for GTN, which are easy for patients to carry around in single-dose form, e.g. in a wallet or jacket pocket, and which simultaneously ensure sufficient stability, simple administration, and rapid onset of action.
  • So-called stick packs or sachets (four-sided sealed pouches) represent an alternative configuration for individual doses, which are becoming increasingly common in the pharmaceutical industry. Stick packs are typically manufactured using composite films consisting of several layers, whereby each individual layer of film performs a specific task (barrier, stiffness, impact resistance, sealing properties, etc.). Here, the barrier layer performs the task of protecting the package contents against substance loss and external contamination. A support layer stabilizes the packaging, enabling it to withstand mechanical stresses, while the sealing layer serves mainly to seal the film package. It is usually made of a thermoplastic polymer and is located on the side of the composite film facing the filling material. Stick packs can be manufactured to contain the pharmaceutical preparation as flowable granules or powder and enable both comfortable transport of the medicinal product as well as simple, easy and reproducible dosing, which is especially significant in emergency situations. However, GTN granules—with their substantially larger total surface area as compared to tablets—pose an even greater challenge with respect to the stabilization of the preparation in any type of packaging configuration including stick packs. In the case of GTN, the highest possible storage stability is especially critical to enable the patient to carry around a single dose such as, but not limited to a stick pack. However, carrying it around in the breast pocket of a shirt, for example, can subject it to significant temperature increases and associated stress conditions, which may violate the recommended storage conditions for GTN preparations.
  • Another kind of a pharmaceutical preparation that is available in the form of a single dose applicable to the oral mucosa is an oral fast dissolving film (OFDF). This delivery system consists of a slim oral strip, which can be easily placed on the oromucosal tissue. Saliva instantly wets the OFDF, which rapidly hydrates and adheres onto the site of application followed by its rapid disintegration and release of the contained drug substance.
  • It is known from the prior art that GTN has a high affinity for organic materials. Thus, according to Schou, S. A. (Pharmaceutica acta Helvetiae, 34, 1959, 309-330), the use of organic materials, such as cork, cotton, paper, and especially rubber and polyethylene to store GTN-containing tablets must be avoided. Banes (Journal of Pharmaceutical Sciences, 57, 1968, 893) reported GTN loss in tablets packaged individually in aluminum foil films containing a sealing layer made of polyethylene. Following storage, the tablets were found to have less than 10% of the active substance they originally contained, while the majority of the GTN was found in the sealing layer of the packaging material. This effect was attributed to the volatility of GTN at room temperature as well as the high permeability of the plastic for GTN. Polypropylene and polyvinyl chloride appear to behave similarly to a polyethylene, which was discovered to contain 84% of the active substance originally contained in the tablets. Edelman et al. (Journal of the American Pharmaceutical Society, NS11, 1971, 30-33) reported on studies in which the stability of GTN tablets was tested based on the material of the storage container. Here, several tablets were packaged in containers made of glass or polystyrene and stored for 60 days at 25° C. and 50° C., respectively. The results revealed a significant drop in the GTN content of the tablets packaged in plastic containers, while the content of the tablets stored in glass containers remained essentially stable. Tablets packaged individually in blisters and stored under the conditions described above were found to have an even lower GTN content than the tablets stored together in plastic containers. GTN loss occurred regardless of whether the tablets were packaged in plastic-aluminum blisters or in aluminum-aluminum blisters. As a result, storage of GTN tablets in blisters was not recommendable and GTN tablets for sublingual administration are still not available on the market in single-dose units packaged in blisters. Taken together it is common knowledge of pharmaceutical experts that solid preparations containing GTN as active substance can not be packaged in plastic materials.
  • International guidelines require that medicinal products must remain stable for six months at 40° C. and a relative humidity of 75% and—depending on climate zone—for the entire shelf life at 30° C. and a relative humidity of 65% or at 25° C. and a relative humidity of 60%. For logistic and marketing reasons, manufacturers usually aim for a shelf life of at least two years. However, due to the volatility of the active substance and its affinity for plastics, this shelf life is rarely achieved in the case of GTN-containing preparations. There thus continues to be a need for stable GTN-containing preparations having a sufficient shelf life, which are able to be provided in a single dose.
  • A primary packaging material suitable for the production of individual doses, e.g. in the form of stick packs, must be flexible and sufficiently stable in order to avoid being destroyed during transport. In addition, the packaging material must be inert and impervious to the active substance as well as to impurities, which can reach the preparation from the outside.
  • A series of materials is available in the form of composite films for the production of stick packs, sachets and blisters. Among these, aluminum composite films are especially suited for the packaging of pharmaceutical preparations which should be protected from external influences. They exhibit the following layer structure:
      • Paper—Aluminum—Sealing medium
      • Polyethylene terephthalate (PET)—Aluminum—Sealing medium
  • Both, paper as well as PET, serve as the support layer and increase the mechanical stability of the packaging, while aluminum serves as the barrier layer.
  • These films possess suitable mechanical stability and are impervious to both external contaminants as well as to volatile substances contained in the preparation. The paper or PET layer is located on the external surface of the packaging and can be imprinted for their identification. The surface of the aluminum film coming into contact with the filling material is provided with a sealing medium. Sealing materials differ in certain physico-chemical properties, e.g. the softening temperature and a possible interaction with the components of the pharmaceutical preparation. Available materials include composite films with polyethylene (PE), polypropylene (PP), low-density polyethylene (LDPE) or polyacrylonitrile (PAN) as sealing layer. The goals of an effective sealing process are 100% tightness of the packages, maximum throughput and protection of the pharmaceutical preparation from thermal stress. The sealant strongly influences these parameters and thus the industrial applicability of the process.
  • In the sense of this invention the term PAN comprises polyacrylonitrile as well as copolymers of acrylonitrile units and one or more other monomers (AN-copolymers) such as acrylonitrile-methylacrylate copolymer.
  • In addition to aluminum-aluminum blisters, blisters consisting of an aluminum push-through foil and a thermoplastic film are also available for packaging tablets. Suitable thermoplastic films include thermoplastic composite films, which typically consist of multiple layers of different plastics, such as PE, PVC, PP, LDPE or PAN. The mentioned packaging materials are also suitable for other kinds of dosage forms available for individual doses such as powders and orally fast dissolving films.
  • Thus, the object of the present invention is to provide a solid pharmaceutical preparation containing GTN for oral and oromucosal (such as sublingual or buccal) administration in the form of individually packaged single doses having good storage stability.
  • This object is attained by the provision of a stable medicament comprising a solid pharmaceutical preparation containing the active substance GTN for oral or oromucosal administration in the form of one or more individual doses, wherein the one or more individual doses are packaged in aluminium composite films or thermoplastic blister films, which contain a layer comprising PAN on the side facing the preparation. Thus, the present invention exploits the finding that against the expectation of a person skilled in the art thermoplastic materials could be found that exhibit minimal interaction with GTN.
  • Within the framework of the investigations upon which the present invention is based, it was surprisingly found that solid GTN-containing preparations remain stable for the required time period if they are packaged in composite films containing a layer comprising PAN on the surface facing the product. Preferred are aluminum composite films containing a sealing layer comprising an acrylonitrile-methylacrylate copolymer, while aluminium composite films containing a sealing layer made of an impact-modified acrylonitrile-methylacrylate copolymer are particularly preferred. Such barrier plastics are marketed, among others, under the commercial names Barex® 210 or Barex® 218. The preparations according to the invention are packaged as individual doses which remain stable for a storage period of at least 6 months at 40° C. and 75% relative humidity.
  • The preferred pharmaceutical preparation is an oromucosal, solid, GTN-containing preparation, preferably a GTN-containing, flowable powder or flowable granules, respectively, for sublingual administration, which may optionally be pressed into a sublingual tablet.
  • The pharmaceutical preparation contains 0.05 to 2 weight % GTN; GTN concentrations of 0.10, 0.20, 0.25, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 1.0, 1.2, 1.4, 1.6 or 1.8 weight % are especially preferred. Unless otherwise stated, all weight percentages are based on the total weight of the preparation.
  • The pharmaceutical preparation according to the invention may contain one or more other pharmaceutical excipients, which support sublingual release of the active substance and which are selected from water-soluble mono-, di-, and polysaccharides, as well as their alcohols. These excipients are especially selected from fructose, glucose, isomalt, lactose, maltitol, maltose, mannitol, saccharose, sorbitol, trehalose and xylitol, and mixtures thereof. These excipients are preferably present in a total content of 90 to 98 weight %. In the case of mixtures, the concentration of each individual substance is 20 to 70 weight %, whereby the preferred contents include 25, 30, 35, 40, 45, 50, 55, 60 or 65 weight %.
  • The preparation according to the invention may optionally be provided with a coating. In addition, the preparation according to the invention may contain other excipients, such as flavoring agents. Flavoring agents are used especially in the case of preparations for oral or sublingual administration in order to increase acceptance among patients. According to the invention, they are preferably used at concentrations of 0.01 to 3.0 weight %, whereby the especially preferred concentrations include 0.5, 1, 1.5, 2 or 2.5 weight %.
  • Due to its explosive properties, GTN intended for pharmaceutical purposes is phlegmatized by the manufacturer, i.e. embedded in a matrix, which reduces the risk posed by the hazardous properties. The matrix can be in liquid or in powder form. For example, GTN is available as a 5% solution in medium-chain triglycerides, such as Miglyol® 812 or Miglyol® 840, or propylene glycol, as a 10% lactose triturate or a 2.25% dilution in glucose. If these GTN concentrates are used for producing the pharmaceutical preparation according to the invention, the agent used for phlegmatization of GTN is regularly contained in the finished product. If GTN is phlegmatized in a volatile solvent like ethanol, the solvent can be lost during the production process.
    • EXAMPLES
  • The following examples illustrate various preparations according to the invention and methods of their preparation.
  • GTN was used as a 5% concentrate in Miglyol® 812. Unless otherwise stated, the optionally pre-granulated excipients were processed into a homogenous mixture with the GTN concentrate.
    • Example 1
  • Ingredients Amount [g]
    Isomalt 68.35
    Xylitol 25.00
    GTN 0.21
    Medium-chain triglycerides* 3.78
    Flavoring agent 1.61
    Caprylic/Capric glycerides** 1.01
    Total 99.96
    *Commercial name: Miglyol 812
    **Commercial name: Imwitor 742
  • The granules according to Example 1 were packaged in the packaging materials referred to in Examples 2 through 5 and stored for 12 weeks at 25° C. and 60% relative humidity and at 40° C. and 75% relative humidity. As a reference, granules were stored in open dishes and in glass containers.
    • Comparative Example 2
  • PET—aluminum—75 μm LDPE (low-density polyethylene)
    • Comparative Example 3
  • PET—aluminum—40 μm LDPE
    • Comparative Example 4
  • PET—aluminum—50 μm PP (polypropylene)
    • Example (according to the invention) 5
  • PET—aluminum—50 μm PAN (Barex® 210)
  • After four and 12 weeks of storage, samples were taken and the GTN content was quantified using HPLC analysis. Thereby a quantity of powder or granules corresponding to a single dose was dissolved in a suitable solvent. GTN was detected using a UV-VIS detector at a wavelength of 225 nm.
  • The results are shown in the table below:
  • GTN content GTN content
    in % of initial in % of initial
    content following content following
    storage at storage at
    25° C. 40° C.
    Packaging 4 weeks 12 weeks 4 weeks 12 weeks
    Open storage n.m. n.m. 60% 17%
    Comp. example 2 72% 53% 51% n.m.
    Comp. example 3 76% 66% 66% n.m.
    Comp. example 4 94% 85% 78% n.m.
    Example 5 97% 97% 97% 95%
    Glass 103%  104%  102%  98%
    n.m. = not measured (The results after four weeks were so poor in the case of some of the film materials that the test was terminated.)
  • The results demonstrate that the GTN containing preparation, when stored in a composite film containing a layer comprising PAN at the side faced with the preparation, especially in a composite film containing an impact-modified acrylonitrile-methylacrylate copolymer as the layer coming into contact with the pharmaceutical product, achieve the same stability as the pharmaceutical preparation when stored in a glass container. By contrast a significant active substance loss occurred, when the GTN containing preparation is packed in composite films comprising a different sealing layer such as LPDE or PP on the side facing the preparation.
  • The preparation according to the present invention can be supplied as individual dose, e.g. within a stick pack or sachet, wherein the aluminum composite film contains a layer comprising PAN on the side facing the preparation. In addition, it is possible to prepare tablets, mini-tablets or pellets for sublingual administration from granules, if necessary, following the addition of other pharmaceutically acceptable excipients such as fillers, disintegrants, glidants, binders, and lubricants, or to fill the granules into hard gelatin two-piece capsules. Single doses of GTN in form of tablets, pellets or capsules can likewise be filled in stick packs and sachets or packaged in blisters, whose thermoplastic film surface contains a layer comprising PAN on the side facing the preparation. The same applies to single doses of GTN available in the form of oral fast dissolving films, which can be packed into aluminium or thermoplastic composite films carrying a layer comprising PAN at the surface, which is in direct contact with the preparation.

Claims (15)

1-13. (canceled)
14. A solid pharmaceutical preparation, comprising: glyceryl trinitrate (GTN) packaged in a composite film, wherein the composite film contains a layer comprising polyacrylonitrile (PAN) on the side facing the pharmaceutical preparation.
15. The pharmaceutical preparation of claim 14, wherein the composite film is an aluminum composite film.
16. The pharmaceutical preparation of claim 14, wherein the composite film is a thermoplastic composite film.
17. The pharmaceutical preparation of claim 14, wherein the layer of the composite film on the side facing the pharmaceutical preparation comprises acrylonitrile-methylacrylate copolymer.
18. The pharmaceutical preparation of claim 14, wherein the layer of the composite film on the side facing the pharmaceutical preparation comprises impact-modified acrylonitrile-methylacrylate copolymer.
19. The pharmaceutical preparation of claim 14, wherein the GTN content is between 0.05 and 2% by weight.
20. The pharmaceutical preparation of claim 14, further comprising at least one other excipient suitable for sublingual administration selected from the group consisting of fructose, glucose, isomalt, lactose, maltitol, maltose, mannitol, saccharose, sorbitol, trehalose and xylitol, and mixtures thereof.
21. The pharmaceutical preparation of claim 20, wherein the at least one other excipient suitable for sublingual administration is xylitol and/or isomalt at concentrations of 20 to 95% by weight.
22. The pharmaceutical preparation of claim 14, further comprising at least one flavoring agent.
23. The pharmaceutical preparation of claim 14, wherein the GTN is formulated in the form of granules.
24. The pharmaceutical preparation of claim 14, wherein the GTN is formulated in the form of a tablet.
25. The pharmaceutical preparation of claim 14, wherein the GTN is formulated in the form of an oral fast dissolving film.
26. The pharmaceutical preparation of claim 14, wherein the GTN is packaged in the form of a single dose for oromucosal or oral administration.
27. The pharmaceutical preparation of claim 26, wherein the single dose form is contained in a stick pack.
US14/001,032 2011-02-25 2012-02-24 Packaging of Solid Pharmaceutical Preparations Containing the Active Substance Glyceryl Trinitrate Abandoned US20130327676A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011012491 2011-02-25
DE102011012491.8 2011-02-25
PCT/EP2012/000802 WO2012113563A1 (en) 2011-02-25 2012-02-24 Packaging of solid pharmaceutical preparations containing the active substance glyceryl trinitrate

Publications (1)

Publication Number Publication Date
US20130327676A1 true US20130327676A1 (en) 2013-12-12

Family

ID=45787158

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/001,018 Abandoned US20130331461A1 (en) 2011-02-25 2012-02-24 Stabilized Granules Containing Glyceryl Trinitrate
US14/001,032 Abandoned US20130327676A1 (en) 2011-02-25 2012-02-24 Packaging of Solid Pharmaceutical Preparations Containing the Active Substance Glyceryl Trinitrate
US14/473,415 Active 2032-03-11 US9101592B2 (en) 2011-02-25 2014-08-29 Stabilized granules containing glyceryl trinitrate
US14/792,158 Expired - Fee Related US9616023B2 (en) 2011-02-25 2015-07-06 Stabilized granules containing glyceryl trinitrate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/001,018 Abandoned US20130331461A1 (en) 2011-02-25 2012-02-24 Stabilized Granules Containing Glyceryl Trinitrate

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/473,415 Active 2032-03-11 US9101592B2 (en) 2011-02-25 2014-08-29 Stabilized granules containing glyceryl trinitrate
US14/792,158 Expired - Fee Related US9616023B2 (en) 2011-02-25 2015-07-06 Stabilized granules containing glyceryl trinitrate

Country Status (7)

Country Link
US (4) US20130331461A1 (en)
EP (3) EP2678000B1 (en)
AU (2) AU2012219926B2 (en)
CA (2) CA2827716C (en)
ES (2) ES2672261T3 (en)
PL (2) PL2678000T3 (en)
WO (2) WO2012113564A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668947B1 (en) * 2012-05-31 2016-11-30 G. Pohl-Boskamp GmbH & Co. KG Induction of arteriogenesis with a nitric oxide-donor such as nitroglycerin
WO2019009927A1 (en) * 2017-07-06 2019-01-10 Adorus Pharmaceuticals Llc Blend compositions for oral administration as a rapidly dissolving powder and/or suspension

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1125882A (en) * 1963-09-18 1968-09-05 Key Pharma Improvements in a delayed and sustained release type pharmaceutical preparation
GB1343374A (en) * 1971-06-01 1974-01-10 Parke Davis & Co Pharmaceutical compositions and process for their production
US6443307B1 (en) * 2000-01-25 2002-09-03 Michael D. Burridge Medication dispenser with an internal ejector
CN101229148A (en) * 2007-12-28 2008-07-30 天津医科大学 Preparation of orally (sublingual) disintegrating tablet of nitroglycerin and its preparation method
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
US7781226B2 (en) * 2004-02-27 2010-08-24 The Board Of Regents Of The University Of Texas System Particle on membrane assay system
US20110002987A1 (en) * 2008-03-05 2011-01-06 Rivopharm Sa Nicorandil Carriers with Enhanced Stability

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE632504A (en) 1962-05-24
GB1205019A (en) * 1966-12-07 1970-09-09 Sterwin Ag Improvements in or relating to oral dosage forms
JPS599539B2 (en) 1979-11-13 1984-03-03 日本化薬株式会社 Nitroglycerin aqueous solution and its manufacturing method
CA1163195A (en) 1980-06-26 1984-03-06 Alec D. Keith Polymeric diffusion matrix containing a vasodilator
US4542013A (en) * 1981-07-08 1985-09-17 Key Pharmaceuticals, Inc. Trinitroglycerol sustained release vehicles and preparation therefrom
DE3246081A1 (en) 1982-12-13 1984-06-14 G. Pohl-Boskamp GmbH & Co Chemisch-pharmazeutische Fabrik, 2214 Hohenlockstedt Nitroglycerin spray
JP2845913B2 (en) 1987-01-23 1999-01-13 ザ・ゼネラル・ホスピタル・コーポレイション Atriopeptin, guanylate cyclase activator, and phosphodiesterase inhibitor for the treatment of glaucoma, hydrocephalus, and cerebral edema (cranial fluid abnormalities)
JPH0645538B2 (en) 1987-09-30 1994-06-15 日本化薬株式会社 Nitroglycerin spray
HU199678B (en) 1988-07-08 1990-03-28 Egyt Gyogyszervegyeszeti Gyar Process for producing aerosols containing nitroglicerol
DE4007705C1 (en) 1990-03-10 1991-09-26 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
DE4018919C2 (en) 1990-06-13 1994-08-25 Sanol Arznei Schwarz Gmbh Nitroglycerin spray
US5370862A (en) 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
DE4026072A1 (en) 1990-08-17 1992-02-20 Sanol Arznei Schwarz Gmbh NITROGLYCER-CONTAINING, HYDROPHILIC, WAESSRING PUMPSPRAY
DE4038203A1 (en) 1990-11-30 1992-06-04 Kali Chemie Pharma Gmbh Pharmaceutical spray-prepn. for admin. of nitrate(s) - esp. for treatment of cardiovascular, disorders, asthma, migraine and colic
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5869082A (en) 1996-04-12 1999-02-09 Flemington Pharmaceutical Corp. Buccal, non-polar spray for nitroglycerin
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
US20030095925A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
NZ502878A (en) * 1997-10-03 2002-03-01 Warner Lambert Co Compressed nitroglycerin tablet containing glyceryl monstearate as a stabilizer
US6796966B2 (en) 1997-10-15 2004-09-28 Jeffrey E. Thomas Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal
AU2479099A (en) 1998-01-28 1999-08-16 Seatrace Pharmaceuticals, Inc. Topical vasodilatory gel composition and methods of use and production
US5989529A (en) 1998-11-20 1999-11-23 Schering-Plough Healthcare Products, Inc. Substantive topical composition
IT1303793B1 (en) * 1998-11-27 2001-02-23 Promefarm S R L "PHARMACEUTICAL COMPOSITION INCLUDING A DONOR ORGANIC COMPOUND OF NITRIC OXIDE (NO)"
US6962691B1 (en) 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
RU2174838C2 (en) 1999-11-04 2001-10-20 Ивановская государственная медицинская академия Method for treating severe manifestations of bronchial obstructive syndrome in children
US20020049188A1 (en) 1999-12-15 2002-04-25 Azarnoff Daniel L. Nitroglycerin ointment for treatment of pain associated with anal disease
US20010048987A1 (en) * 2000-03-14 2001-12-06 David Kanios Packaging materials for transdermal drug delivery systems
US6538033B2 (en) 2000-08-29 2003-03-25 Huntington Medical Research Institutes Nitric oxide donor compounds
CN1545421A (en) 2001-06-22 2004-11-10 �Ʒ� Pharmaceutical compositions of drugs and neutralized acidic polymers
DE60309440T2 (en) * 2002-02-08 2007-10-11 The Procter & Gamble Company, Cincinnati CHILD-SAFE PACKAGING
US20050095278A1 (en) 2003-01-14 2005-05-05 Viorel Nicolaescu Use of nitroglycerin to relieve nocturnal muscle cramps
US20040228883A1 (en) 2003-02-21 2004-11-18 Mitchell Karl Prepackaged aqueous pharmaceutical formulation for the treatment of cardiac conditions containing at least two different active agents and method of formulation
WO2005004989A2 (en) 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
US20070053966A1 (en) 2003-10-17 2007-03-08 Robert Ang Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue
WO2005084301A2 (en) 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
WO2005107461A2 (en) 2004-04-07 2005-11-17 The General Hospital Corporation Modulating lymphatic function
EP1971344B1 (en) 2006-01-09 2010-09-22 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
WO2007123955A2 (en) 2006-04-19 2007-11-01 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
DE102008005484A1 (en) 2008-01-22 2009-07-23 Schaper, Wolfgang, Dr. Induction and promotion of arteriogenesis
US20100184870A1 (en) 2008-03-14 2010-07-22 Rolf Groteluschen Long-term stable pharmaceutical preparation containing the active ingredient glycerol trinitrate
DE202008007318U1 (en) 2008-03-14 2008-07-31 G. Pohl-Boskamp Gmbh & Co. Kg Long-term stable pharmaceutical preparation with the active ingredient glycerol trinitrate
EP2379070A4 (en) 2008-07-21 2013-11-13 Imi Internat Medical Innovations D B A Procris Pharmaceuticals Stable water-based topical pharmaceutical creams and methods of making and using same
JP2011010865A (en) 2009-06-30 2011-01-20 Ikaria Holdings Inc Method of treating term and near-term neonate having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1125882A (en) * 1963-09-18 1968-09-05 Key Pharma Improvements in a delayed and sustained release type pharmaceutical preparation
GB1343374A (en) * 1971-06-01 1974-01-10 Parke Davis & Co Pharmaceutical compositions and process for their production
US6443307B1 (en) * 2000-01-25 2002-09-03 Michael D. Burridge Medication dispenser with an internal ejector
US7781226B2 (en) * 2004-02-27 2010-08-24 The Board Of Regents Of The University Of Texas System Particle on membrane assay system
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
CN101229148A (en) * 2007-12-28 2008-07-30 天津医科大学 Preparation of orally (sublingual) disintegrating tablet of nitroglycerin and its preparation method
US20110002987A1 (en) * 2008-03-05 2011-01-06 Rivopharm Sa Nicorandil Carriers with Enhanced Stability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Richman et al., Preparation and Stability of Glyceryl Trinitrate Sublingual Tablets Prepared by Direct Compression, 1965, Journal of Pharmaceutical Sciences, Vol. 54, No. 3, pp.447-451 *

Also Published As

Publication number Publication date
AU2012219925B2 (en) 2017-02-23
WO2012113563A1 (en) 2012-08-30
CA2827716A1 (en) 2012-08-30
US9101592B2 (en) 2015-08-11
CA2827714A1 (en) 2012-08-30
EP2678000B1 (en) 2018-03-07
US9616023B2 (en) 2017-04-11
AU2012219926B2 (en) 2016-11-17
ES2565632T3 (en) 2016-04-06
AU2012219925A1 (en) 2013-10-03
EP3354259A1 (en) 2018-08-01
PL2678006T3 (en) 2016-06-30
EP2678006A1 (en) 2014-01-01
US20130331461A1 (en) 2013-12-12
US20160000711A1 (en) 2016-01-07
EP2678006B1 (en) 2015-12-30
US20140370109A1 (en) 2014-12-18
AU2012219926A1 (en) 2013-09-12
ES2672261T3 (en) 2018-06-13
EP2678000A1 (en) 2014-01-01
WO2012113564A1 (en) 2012-08-30
CA2827716C (en) 2019-05-14
PL2678000T3 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
CN102164585B (en) Compositions containing amlodipine and bisoprolol
MX2011003510A (en) Method of making a multilayer adhesive laminate.
KR101461841B1 (en) Pharmaceuticals
US20200289402A1 (en) Pouch-type orally dissolving films with high active ingredient concentration
AU2012219925B2 (en) Packaging of solid pharmaceutical preparations containing the active substance glyceryl trinitrate
JP2020070285A (en) Medicine
AU2014203766B2 (en) Pack of medicinal tablets
JP7264606B2 (en) pharmaceuticals
WO2020138407A1 (en) Medicinal product
JP2022084568A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: G. POHL-BOSKAMP GMBH & CO. KG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZIMMECK, THOMAS;UECK, HENNING;GEHRICKE (NEE ZSCHERPE), JULIA;REEL/FRAME:031574/0319

Effective date: 20131031

AS Assignment

Owner name: G. POHL-BOSKAMP GMBH & CO. KG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZIMMECK, THOMAS;UECK, HENNING;GEHRICKE (NEE ZSCHERPE), JULIA;REEL/FRAME:036096/0280

Effective date: 20131031

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载